Group 1 - Novo Nordisk's stock rose by 1.76% in pre-market trading following the announcement of the approval of oral Semaglutide by European regulators [1] - The European Medicines Agency approved a label update for Rybelsus to reflect its cardiovascular protective effects [1] - Clinical trials indicated that Rybelsus can reduce the risk of cardiovascular death, heart attack, and stroke by 14% in high-risk adult patients with type 2 diabetes compared to a placebo [1] Group 2 - As of September 15, the closing price of Novo Nordisk was $55.620, with a pre-market price of $56.600 [1] - The total market capitalization of Novo Nordisk is approximately $246.99 billion [1] - The stock has a 52-week high of $124.107 and a low of $44.548 [1]